VX-680 (Tozasertib, MK-0457)

Catalog No.S1048

VX-680 (Tozasertib, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

Price Stock Quantity  
USD 134 In stock
USD 147 In stock
USD 370 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

VX-680 (Tozasertib, MK-0457) Chemical Structure

VX-680 (Tozasertib, MK-0457) Chemical Structure
Molecular Weight: 464.59

Validation & Quality Control

Cited by 35 publications:

15 customer reviews :

Quality Control & MSDS

Related Compound Libraries

VX-680 (Tozasertib, MK-0457) is available in the following compound libraries:

Aurora Kinase Inhibitors with Unique Features

  • Pan Aurora Kinase Inhibitors

    Danusertib (PHA-739358) Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM. SNS-314 Mesylate Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.

  • Most Potent Aurora Kinase Inhibitor

    MK-5108 (VX-689) Aurora A, IC50=0.064 nM.

  • Aurora Kinase Inhibitor in Clinical Trial

    Alisertib (MLN8237) Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.

  • Classic Aurora Kinase Inhibitor

    Hesperadin Potently inhibits Aurora B with IC50 of 250 nM.

Product Information

  • Compare Aurora Kinase Inhibitors
    Compare Aurora Kinase Products
  • Research Area
  • Inhibition Profile
  • VX-680 (Tozasertib, MK-0457) Mechanism

Product Description

Biological Activity

Description VX-680 (Tozasertib, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.
Targets Aurora A [1]
(Cell-free assay)
Aurora C [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
FLT3 [4]
(Cell-free assay)
Bcr-Abl [4]
(Cell-free assay)
IC50 0.6 nM(Ki app) 4.6 nM(Ki app) 18 nM(Ki app) 30 nM(Ki) 30 nM(Ki)
In vitro Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150  nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12  hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. [2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
BE-13MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\ScpV[UUN3ME2wMlAxOzN6IN88US=>MojUV2FPT1KHUh?=
RS4-11MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnqTWM2OD1yLkCwOFA1KM7:TR?=MlzwV2FPT1KHUh?=
MFH-inoNIXNWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTBwMEC5PUDPxE1?MUHTRW5IWkWU
NTERA-S-cl-D1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTBwMEG0N|Qh|ryPM1rNbHNCVkeURWK=
697NGr2WYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\qPINKSzVyPUCuNFI1PzFizszNMn;GV2FPT1KHUh?=
NALM-6NH;F[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHr0ZWpKSzVyPUCuNFI2PTJizszNM3SzUHNCVkeURWK=
ES8M2fIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfjTWM2OD1yLkC0OlE{KM7:TR?=MYHTRW5IWkWU
HUTU-80NULyV3RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2X5TWlEPTB;MD6wOVI6QSEQvF2=MlXhV2FPT1KHUh?=
MV-4-11MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrIRnBKSzVyPUCuNFc4QDJizszNMY\TRW5IWkWU
MONO-MAC-6NF7S[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnkcndtUUN3ME2wMlA4QDd7IN88US=>NH;KdW1USU6JUlXS
LC-2-adNXPVe|hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTBwMEi3PFkh|ryPNFnDd21USU6JUlXS
BL-41MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmm1TWM2OD1yLkGwOFQ2KM7:TR?=NUDpV2pUW0GQR2LFVi=>
A4-FukNYroXFdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULo[FNQUUN3ME2wMlEyPTZ|IN88US=>Mn;rV2FPT1KHUh?=
SW954M4DPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULRO2d3UUN3ME2wMlEzOjJ7IN88US=>M{Pmd3NCVkeURWK=
BV-173MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfDTWM2OD1yLkGyOlQyKM7:TR?=NITXZmpUSU6JUlXS
TE-11NFPqO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIOyZ2FKSzVyPUCuNVQ6QDJizszNM3Xx[3NCVkeURWK=
SK-UT-1MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTBwMUW5OlUh|ryPM32yWHNCVkeURWK=
SIG-M5MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTzUGpCUUN3ME2wMlE3PzB5IN88US=>MmL6V2FPT1KHUh?=
OCUB-MNXTUcnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLpTWM2OD1yLkG2PVg{KM7:TR?=MoH5V2FPT1KHUh?=
K052MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzZcZhCUUN3ME2wMlE6PDhizszNMVzTRW5IWkWU
VA-ES-BJM1;zNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3oT2poUUN3ME2wMlIxODh4IN88US=>MlfiV2FPT1KHUh?=
SW982NILzUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF6wTVlKSzVyPUCuNlE{QCEQvF2=NVrtUpgxW0GQR2LFVi=>
LB647-SCLCM1LmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDjZ2ZKSzVyPUCuNlE2OjNizszNNWW0eHFDW0GQR2LFVi=>
PSN1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFqwSnFKSzVyPUCuNlIxOjZizszNNVTVVVl4W0GQR2LFVi=>
BB30-HNCM3S0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTBwMkK1PVEh|ryPNVWySXh2W0GQR2LFVi=>
ST486MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTBwMkOwPFch|ryPM2DnWnNCVkeURWK=
MOLT-4MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXmVYhSUUN3ME2wMlI{OzN5IN88US=>MVnTRW5IWkWU
EW-16NHPMbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH[xc3pKSzVyPUCuNlM4PjhizszNMYDTRW5IWkWU
KS-1NEnTO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm[4TWM2OD1yLkKzO|g2KM7:TR?=MnzRV2FPT1KHUh?=
SRM2rpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnexTWM2OD1yLkK0OVY1KM7:TR?=MYDTRW5IWkWU
KM12MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTBwMk[zOkDPxE1?MVjTRW5IWkWU
EM-2NWSxcndZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nhOGlEPTB;MD6yOlY1OSEQvF2=NYXhdmVXW0GQR2LFVi=>
MEG-01M{n0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlX2TWM2OD1yLkK3PFQ6KM7:TR?=NUHpdpdEW0GQR2LFVi=>
NB13MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\aTWM2OD1yLkK3PVg1KM7:TR?=MnXZV2FPT1KHUh?=
RKONF\0UIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TKbmlEPTB;MD6zNFgyOyEQvF2=M4TWTnNCVkeURWK=
CESSMmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnacG5KSzVyPUCuN|E{OjhizszNNGn2WopUSU6JUlXS
EoL-1-cellMnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVH2RnloUUN3ME2wMlM{PDV7IN88US=>NUPVUWk{W0GQR2LFVi=>
DOHH-2Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnudlNRUUN3ME2wMlM{PzhzIN88US=>NFvBS|lUSU6JUlXS
A388MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHwTWM2OD1yLkO0NFg3KM7:TR?=M37Xd3NCVkeURWK=
LAMA-84MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NImyfVVKSzVyPUCuN|UyPzhizszNM173Z3NCVkeURWK=
IMR-5MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfQZ4dKSzVyPUCuN|U2PCEQvF2=MVLTRW5IWkWU
KARPAS-422NWrRT|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHmTWM2OD1yLkO3NlczKM7:TR?=NVrsXnRqW0GQR2LFVi=>
MRK-nu-1M4PJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NID1TphKSzVyPUCuN|gyOyEQvF2=Mn;MV2FPT1KHUh?=
BL-70NHvOTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HUUmlEPTB;MD6zPFk4PCEQvF2=MmHjV2FPT1KHUh?=
LXF-289M1rvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTBwNEC0NFYh|ryPNFLDc|FUSU6JUlXS
RL95-2M1T5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLmTWM2OD1yLkSwOVY4KM7:TR?=NVLzZ21vW0GQR2LFVi=>
QIMR-WILNVfXZlRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\0R2lEPTB;MD60NlY4PiEQvF2=M3\qXHNCVkeURWK=
K-562Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPWbGhKSzVyPUCuOFM1PzJizszNNVrYWVJTW0GQR2LFVi=>
NCI-H510AMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFezeohKSzVyPUCuOFM5OjNizszNMXzTRW5IWkWU
NCI-H524M{OxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37U[2lEPTB;MD61NVE1PyEQvF2=MXLTRW5IWkWU
KE-37M3\BVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwNUKxNFIh|ryPNFXYTXBUSU6JUlXS
KP-N-YSM3fIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnW0TWM2OD1yLkW0N|kzKM7:TR?=MW\TRW5IWkWU
LS-411NMoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnzcG1EUUN3ME2wMlU4PzV{IN88US=>NEfpSW9USU6JUlXS
CTV-1MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTBwNUi3O|Mh|ryPM2PPXXNCVkeURWK=
NCI-SNU-16M1zI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVixRlNjUUN3ME2wMlY{PTdzIN88US=>NFPwdGxUSU6JUlXS
HT-144NHXOSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTHbYdKSzVyPUCuOlM4QThizszNM2PTb3NCVkeURWK=
NCI-H187MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\PTWM2OD1yLk[0NVMh|ryPNXLKU5E1W0GQR2LFVi=>
OCI-AML2NUK0elN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTBwNkS0NFMh|ryPNWHiWXZGW0GQR2LFVi=>
CCRF-CEMNVvzd5R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnORY9KSzVyPUCuOlU{PDZizszNM2fDcHNCVkeURWK=
ONS-76MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTBwNk[0OVgh|ryPNHvqcFhUSU6JUlXS
IST-SL2M4\1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrxVYhKSzVyPUCuO|E6QDJizszNNYnxWnF[W0GQR2LFVi=>
NB6NXjQOnRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXOZZhJUUN3ME2wMlc4OjV2IN88US=>NX:xNpZXW0GQR2LFVi=>
SK-PN-DWM2W5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPNTWM2OD1yLke5NVQh|ryPNH3TUnRUSU6JUlXS
HCC1599MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYW4[oVXUUN3ME2wMlgxQDd2IN88US=>MVjTRW5IWkWU
MC116NVm2VG5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\vWJhJUUN3ME2wMlg2ODFzIN88US=>NHXkSZVUSU6JUlXS
TE-15MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PwbGlEPTB;MD64OVA6QCEQvF2=NGPST21USU6JUlXS
HOP-62M{TxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnX1TWM2OD1yLki2N|I6KM7:TR?=M1HSdnNCVkeURWK=
TGBC24TKBNUfuNJFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTBwOE[zPFUh|ryPMn\tV2FPT1KHUh?=
HCE-4Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTBwOEiwOlMh|ryPNFK3NI1USU6JUlXS
ALL-PONUnMOWt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUWzPVMzUUN3ME2wMlg5OTd3IN88US=>MUDTRW5IWkWU
KGNNUHk[Jp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTBwOEm5PVUh|ryPM3SwfHNCVkeURWK=
ML-2NVvLVoRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTBwOUCyOVkh|ryPMnr5V2FPT1KHUh?=
ES4M33KO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;vRW5xUUN3ME2wMlkyOTJ6IN88US=>M2G0[HNCVkeURWK=
SF126MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHDTWM2OD1yLkm0PFE6KM7:TR?=M3\hfHNCVkeURWK=
SK-N-DZM1nl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTBwOU[xPFkh|ryPMmXLV2FPT1KHUh?=
HCC1187NUewZopbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonRTWM2OD1zLkCwOVA2KM7:TR?=MljlV2FPT1KHUh?=
DU-4475NIDTc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIC5[3lKSzVyPUGuNFE4PTZizszNNXzoU2huW0GQR2LFVi=>
NKM-1MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjhPYlKSzVyPUGuNFI4PzVizszNM1r5eXNCVkeURWK=
HL-60M4PHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTFwME[1O|Qh|ryPMoDwV2FPT1KHUh?=
SBC-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTFwMUK1OFIh|ryPMX3TRW5IWkWU
TE-10NX:5[pdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjLfWRKSzVyPUGuNVI6PDZizszNNI\CO|BUSU6JUlXS
ETK-1NU\BXm9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTFwMUO2NVMh|ryPNF;ZOmJUSU6JUlXS
HAL-01NELiTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXO2O2pbUUN3ME2xMlE3PzB7IN88US=>NW\z[5lpW0GQR2LFVi=>
BB65-RCCM3ThNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7HcpFKSzVyPUGuNVgxODVizszNM4\zXHNCVkeURWK=
EW-1NF;XdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTFwMUi1OlIh|ryPMXvTRW5IWkWU
SK-NEP-1NX;ke2NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LvVGlEPTB;MT6yNVEyOSEQvF2=MXjTRW5IWkWU
SK-LMS-1NInBOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk[yTWM2OD1zLkKyNlEzKM7:TR?=NEL2Z2ZUSU6JUlXS
DELM2TQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NID2e5FKSzVyPUGuNlU3PDNizszNNWi5dZUyW0GQR2LFVi=>
GT3TKBNWDFTY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTabWVVUUN3ME2xMlI5ODV5IN88US=>MXPTRW5IWkWU
MOLT-16NHXSfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTFwM{W0NFUh|ryPMkfzV2FPT1KHUh?=
CMKMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfjSVlKSzVyPUGuOFIyOTdizszNMXrTRW5IWkWU
NB5NETUZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTETWM2OD1zLk[0NlI6KM7:TR?=M3W3TXNCVkeURWK=
NCI-H1963M3XiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zi[GlEPTB;MT63NFU5OyEQvF2=MkXRV2FPT1KHUh?=
KURAMOCHIMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXuRlZ5UUN3ME2xMlc5QTFzIN88US=>NGPmdIZUSU6JUlXS
TE-8M1nyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1H3eWlEPTB;MT64NFM3QCEQvF2=MlLTV2FPT1KHUh?=
NCI-H1304MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTFwOEOwO|Mh|ryPMoHyV2FPT1KHUh?=
A101DMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLNTWM2OD1zLki3N|k2KM7:TR?=MmXHV2FPT1KHUh?=
SCLC-21HM3ezeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXWycYlUUUN3ME2xMlk4ODV5IN88US=>NUf1XoJ5W0GQR2LFVi=>
GB-1MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTVSlFKSzVyPUKuNFE3PDdizszNNHHERnFUSU6JUlXS
KARPAS-45M3;aO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV64SlkzUUN3ME2yMlAzPjV2IN88US=>NUK4[mNiW0GQR2LFVi=>
ATN-1M1HBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTJwMEK4OVgh|ryPM3PWR3NCVkeURWK=
NCI-H720M4rEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFm2UlVKSzVyPUKuNFYzPDRizszNMmLIV2FPT1KHUh?=
RPMI-6666M3rBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDuT2RKSzVyPUKuNVYzODdizszNM{nzXHNCVkeURWK=
NB17NGL2XnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTtflJJUUN3ME2yMlI6OjdizszNNV7a[5huW0GQR2LFVi=>
IST-SL1M{XJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTJwMkm3OlUh|ryPMofNV2FPT1KHUh?=
SH-4MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3H[JlLUUN3ME2yMlMzPDZ7IN88US=>MmDtV2FPT1KHUh?=
K5M3\0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vBcWlEPTB;Mj60NFMyQSEQvF2=NUjrcppzW0GQR2LFVi=>
OVCAR-4M2rTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PWcGlEPTB;Mj60OlE{KM7:TR?=NHHWbZhUSU6JUlXS
ACNM3jRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTJwNUCyNVMh|ryPNHvWV|BUSU6JUlXS
TGWMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfKbXZKSzVyPUKuOlU5OzJizszNM2HrSXNCVkeURWK=
NCI-H2107NHyxWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnyTWM2OD1{LkizO|EyKM7:TR?=MXrTRW5IWkWU
NCI-H82NF60SG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvScHBKSzVyPUKuPFM5OzhizszNNEHLSIVUSU6JUlXS
SK-N-FINGXhZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzyTWM2OD1{Lki2PFY5KM7:TR?=NUL3N4tuW0GQR2LFVi=>
LB1047-RCCNU\DXXZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LiSmlEPTB;Mj64PFEzPiEQvF2=MYPTRW5IWkWU
LU-134-AMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTJwOEmyOkDPxE1?MUXTRW5IWkWU
NCI-H209M1LiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\GTWM2OD1{LkmxNlU{KM7:TR?=NFrmZYRUSU6JUlXS
NOMO-1NFO5fVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnSzTWM2OD1|LkCyNlc1KM7:TR?=MXTTRW5IWkWU
RH-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXiTWM2OD1|LkG3NlkyKM7:TR?=NIT3dW9USU6JUlXS
LOUCYNEfwdIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPJ[WdKSzVyPUOuNVg3QTNizszNMnPtV2FPT1KHUh?=
TE-9M{TiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnBTWM2OD1|LkK2O|M3KM7:TR?=NIqx[4tUSU6JUlXS
PF-382M4D5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXxTWM2OD1|LkO1O|c5KM7:TR?=NHjlUGZUSU6JUlXS
RPMI-8402MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXX4d2lSUUN3ME2zMlU5PjB|IN88US=>NVj2WFN4W0GQR2LFVi=>
HELMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHYTWM2OD1|Lk[zNkDPxE1?Ml;JV2FPT1KHUh?=
NOS-1MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknoTWM2OD1|Lki0O|U1KM7:TR?=NYHJdJdyW0GQR2LFVi=>
ES1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPiUWZWUUN3ME2zMlkzOjl|IN88US=>MU\TRW5IWkWU
NCI-H2171NVjvN|FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkn3TWM2OD1|LkmyOFI{KM7:TR?=MoPWV2FPT1KHUh?=
NCI-H747M1TM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTNwOUSyNlEh|ryPNV;Nc5JwW0GQR2LFVi=>
MHH-NB-11Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoL5TWM2OD1|Lkm1N|EzKM7:TR?=Mlv2V2FPT1KHUh?=
MZ1-PCNUW4boxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfrTWM2OD1|Lkm5NlQh|ryPMU\TRW5IWkWU
MMAC-SFMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTRwMEK0Olch|ryPM3zGZXNCVkeURWK=
NMC-G1NHzKSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITO[XBKSzVyPUSuNlI4OjNizszNNFLyPWlUSU6JUlXS
SW872MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTRwM{SzOEDPxE1?M3GxWHNCVkeURWK=
TE-12NVm2Vlh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXaTWM2OD12LkW2N|k1KM7:TR?=M4DjTHNCVkeURWK=
LU-139M4L0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYf1R|NFUUN3ME20MlYyQDN3IN88US=>NGTnZ3pUSU6JUlXS
HC-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLweG1KSzVyPUSuOlk1QTRizszNMXfTRW5IWkWU
COR-L279NWXpb41XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTRwN{W4PVEh|ryPNI\6S3VUSU6JUlXS
SF268Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPrVFNtUUN3ME20Mlc6QTF4IN88US=>NETIfJNUSU6JUlXS
MC-CARM2\3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTVwME[3OVch|ryPM2HIVnNCVkeURWK=
TK10M33aSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYq0cHY1UUN3ME21MlM2PDZ7IN88US=>M13ve3NCVkeURWK=
TE-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2q1cmlEPTB;NT60PVAxPCEQvF2=NHHiWmxUSU6JUlXS
NCI-H2126MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Tn[2lEPTB;NT62OFU4PCEQvF2=M4nMPHNCVkeURWK=
DaudiM2L6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfOcXZKSzVyPUWuOlkyOiEQvF2=NEHMSWpUSU6JUlXS
NCI-H1648Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnnSnlKSzVyPUWuPFE1PTRizszNNGn6e5hUSU6JUlXS
OS-RC-2MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlntTWM2OD13Lkm4OVk4KM7:TR?=NVHIOm9bW0GQR2LFVi=>
DJM-1NVTDWnBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPVPVFFUUN3ME22MlM1PjZ4IN88US=>MULTRW5IWkWU
LS-1034NHLhbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nWOWlEPTB;Nj63OVY3KM7:TR?=MWjTRW5IWkWU
NCI-H1581NHfsTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjUblJDUUN3ME22Mlc5PDB3IN88US=>NF;qbGtUSU6JUlXS
UACC-257MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTdwMES1NVIh|ryPMWPTRW5IWkWU
KM-H2M4H5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HiVGlEPTB;Nz6xPFQ2PyEQvF2=MX7TRW5IWkWU
NCI-H1436MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TiOGlEPTB;Nz62PVk{OiEQvF2=MojWV2FPT1KHUh?=
IA-LMM1XBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3vSYU5UUN3ME23Mlg2QSEQvF2=NH6yb3RUSU6JUlXS
NCI-H526NEjhdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzmTWM2OD16LkK1OlM4KM7:TR?=NEnIUIFUSU6JUlXS
GCIYMmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrSTWM2OD16LkO2PVY2KM7:TR?=NYTz[pEyW0GQR2LFVi=>
CP67-MELM1LQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLCOplKSzVyPUiuOVMzPiEQvF2=NEDNS45USU6JUlXS
KALS-1M3jwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2q5WGlEPTB;OD64N|g2OSEQvF2=MU\TRW5IWkWU
NCI-H1770MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHP6Z2hKSzVyPUiuPVAzPjVizszNMWHTRW5IWkWU
8-MG-BAM1HofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPsdGtKSzVyPUmuN|I5PDRizszNMlLBV2FPT1KHUh?=
KY821NHjSTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGf2eYtKSzVyPUmuO|c1QDRizszNMmXEV2FPT1KHUh?=
SNB75MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTFyLkC3OkDPxE1?MWjTRW5IWkWU
NCCITMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\NfJpXUUN3ME2xNU4xPTh{IN88US=>M3rZR3NCVkeURWK=
SJSA-1NGrLU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml32TWM2OD1zMT6yPFkyKM7:TR?=NGexZpZUSU6JUlXS
LB373-MEL-DMn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDyTWM2OD1zMT6zPFI4KM7:TR?=MWTTRW5IWkWU
TALL-1MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\kSGlEPTB;MUGuOFA2QCEQvF2=M371fHNCVkeURWK=
NB69MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;LTWM2OD1zMT63O|A2KM7:TR?=MlXrV2FPT1KHUh?=
NCI-H1355NEDVT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlmyTWM2OD1zMT65OFI3KM7:TR?=NFy1fmdUSU6JUlXS
DMS-153MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTHTWM2OD1zMj6wOFI3KM7:TR?=Mn7JV2FPT1KHUh?=
OPM-2NGi4[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4W0NmlEPTB;MUKuNVU6PiEQvF2=NVu3O3BtW0GQR2LFVi=>
NB1NX:1fpZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rRZWlEPTB;MUKuNlkh|ryPMorBV2FPT1KHUh?=
A3-KAWM2mwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTF{LkOyN|Yh|ryPMmfNV2FPT1KHUh?=
NCI-H1882NHHqU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjVVo1KSzVyPUGyMlQxPjZizszNNUD3OnpKW0GQR2LFVi=>
KG-1Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjVb5VQUUN3ME2xNk43PTR3IN88US=>MX3TRW5IWkWU
LC4-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYS1XFloUUN3ME2xNk44PzB4IN88US=>MYPTRW5IWkWU
HCE-TM1n0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1iwWWlEPTB;MUOuNFA1QSEQvF2=NWjidIE5W0GQR2LFVi=>
NEC8M{G5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zhRWlEPTB;MUOuNVA{QCEQvF2=M1jMU3NCVkeURWK=
IST-MEL1M1\1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3Sy[2lEPTB;MUOuOVc5QCEQvF2=NXyw[4h6W0GQR2LFVi=>
EW-3NGXW[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\PWo9KSzVyPUGzMlc1ODJizszNM{nDZnNCVkeURWK=
CTB-1Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULuc2dqUUN3ME2xOE4xOzJ7IN88US=>M2rtcHNCVkeURWK=
LS-123MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTF2LkG1PFgh|ryPNIOwbZFUSU6JUlXS
NCI-H1417MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;yPFVRUUN3ME2xOE4{ODV{IN88US=>MWTTRW5IWkWU
MZ7-melNVLXXI5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnpcY5IUUN3ME2xOE41PDN|IN88US=>NH7xVHdUSU6JUlXS
JiyoyeP-2003MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PYZmlEPTB;MUWuOlMzPiEQvF2=MXXTRW5IWkWU
ES6Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrLOYNKSzVyPUG2MlI{PjFizszNMm[wV2FPT1KHUh?=
HHNULZXI1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljMTWM2OD1zNz6xPVY{KM7:TR?=NVPXOXZNW0GQR2LFVi=>
SF539MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPBU4tKSzVyPUG3Mlk6OjJizszNMWjTRW5IWkWU
Calu-6NIO0S2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljOTWM2OD1zOT6yN|kh|ryPM3HJZXNCVkeURWK=
SK-MM-2Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjJU|NIUUN3ME2xPU42PTVizszNM{C2dXNCVkeURWK=
IST-MES1NHv5R2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LucmlEPTB;MUmuOlY3OyEQvF2=NITVUWpUSU6JUlXS
GI-ME-NM2\h[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjjepJKSzVyPUG5MlgzOjdizszNNXS0cHpJW0GQR2LFVi=>
CAL-148MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M334TWlEPTB;MkCuPVk{PCEQvF2=MUnTRW5IWkWU
EVSA-TMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnuzTWM2OD1{MT6xOFk6KM7:TR?=MmLQV2FPT1KHUh?=
LP-1NGD2cndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHzdlJ3UUN3ME2yNU4{PDN{IN88US=>MW\TRW5IWkWU
BOKUNEH5d2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIC0OJpKSzVyPUKxMlQ2OzNizszNNVfPcVNSW0GQR2LFVi=>
KLENUfHRVVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\3SWlEPTB;MkKuNVkxOyEQvF2=NW\BXlNIW0GQR2LFVi=>
LB831-BLCNWH5ZZJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHXNGo{UUN3ME2yOU4yPTJ4IN88US=>Mn\FV2FPT1KHUh?=
NCI-H889NYPOPXlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vYc2lEPTB;MkWuNVk{OSEQvF2=NWSycJdNW0GQR2LFVi=>
REHM3HF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\zTWM2OD1{NT60OlcyKM7:TR?=MorjV2FPT1KHUh?=
KP-N-RT-BM-1MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TwNWlEPTB;MkWuOFc2OiEQvF2=MUfTRW5IWkWU
MPP-89Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPPW2NKSzVyPUK1MlU{OTRizszNMWLTRW5IWkWU
no-11MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTJ3Lke0O{DPxE1?M2nlbXNCVkeURWK=
NCI-H748NYfYSXp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUW1TmJvUUN3ME2yOU44PjJ5IN88US=>NXfZeJpYW0GQR2LFVi=>
LB2518-MELMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTJ5LkG3O|Mh|ryPMW\TRW5IWkWU
TGBC1TKBNGjiVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1P1OmlEPTB;MkeuOVU5PSEQvF2=NYfsTYFmW0GQR2LFVi=>
MHH-PREB-1NH7rbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mli4TWM2OD1{OD6wO|M1KM7:TR?=MnruV2FPT1KHUh?=
MZ2-MELMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPMTYlMUUN3ME2yPE43OTR|IN88US=>NWnkcGN6W0GQR2LFVi=>
U-266M4SwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTJ6Lk[zOlYh|ryPNVfaT2o5W0GQR2LFVi=>
SNU-C1NGPKRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;JV3ZrUUN3ME2yPE46PDNizszNMlrFV2FPT1KHUh?=
SW962M3:2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHS[W9IUUN3ME2zNE4zPzR5IN88US=>NHLtNndUSU6JUlXS
RajiMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTNyLkW1PVIh|ryPMlHJV2FPT1KHUh?=
KNS-42NFXPSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7BTphDUUN3ME2zNE45QTV4IN88US=>MnHVV2FPT1KHUh?=
LB996-RCCNHnKWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIWxc3hKSzVyPUOxMlE4ODJizszNMoHzV2FPT1KHUh?=
CHP-126Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTNzLkG5PFQh|ryPM3rjW3NCVkeURWK=
RXF393NWfleWlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFL1PHZKSzVyPUOyMlQ6PyEQvF2=MnvZV2FPT1KHUh?=
COLO-684M{POPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHNTWM2OD1|Mj62OFM5KM7:TR?=NHTGRlZUSU6JUlXS
A704NXLlSWNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInEcXBKSzVyPUOzMlU2OzhizszNMnPVV2FPT1KHUh?=
A253M4SwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXjdYltUUN3ME2zN{42QDV{IN88US=>NEnlT5FUSU6JUlXS
KNS-81-FDNF7MZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HlfmlEPTB;M{SuOVQ2PiEQvF2=NETSPHFUSU6JUlXS
TE-441-TMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zhb2lEPTB;M{SuOlM4OSEQvF2=NFLQV4xUSU6JUlXS
HCC2157MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPTbXVEUUN3ME2zOU41PjF7IN88US=>M4fYeXNCVkeURWK=
ES3M2rxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrMZolKSzVyPUO2MlY4PSEQvF2=NEHuVpVUSU6JUlXS
NCI-H1155NEfRbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfQTWM2OD1|Nz64NVUh|ryPNHyx[otUSU6JUlXS
SNU-C2BNXnGWlIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnndVJLUUN3ME2zPE4yPjV2IN88US=>NWrz[FExW0GQR2LFVi=>
JARMmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLOTWM2OD1|OD6yOFQ6KM7:TR?=NXzLWVdCW0GQR2LFVi=>
GDM-1NEjmRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjhfo04UUN3ME2zPE46OTF4IN88US=>M{nFTnNCVkeURWK=
KU812NVnIN|FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TjUmlEPTB;NEGuOVA4KM7:TR?=Mo\oV2FPT1KHUh?=
BC-1M2TUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTR{Lk[3N|Eh|ryPMVnTRW5IWkWU
GI-1NHrCTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rZWGlEPTB;NEKuPVE6OiEQvF2=NYjacYF4W0GQR2LFVi=>
NCI-H1694MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfrSZZKSzVyPUS0Mlk1PzJizszNMmHLV2FPT1KHUh?=
DG-75MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moe3TWM2OD12NT6xOVc4KM7:TR?=M1fmUnNCVkeURWK=
COR-L88M2n0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2P2TWlEPTB;NEWuNlc4QCEQvF2=MmHDV2FPT1KHUh?=
LS-513NUG1c4RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIS2R|FKSzVyPUS1MlkyPTZizszNNUXrXZRqW0GQR2LFVi=>
HD-MY-ZNUi0e5psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF36ZmpKSzVyPUS2MlQ3OTJizszNM3LxRnNCVkeURWK=
L-363NEfLcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTR4Lki4NUDPxE1?MmXEV2FPT1KHUh?=
TE-6MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PrZ2lEPTB;NEiuOFQ3KM7:TR?=Mne5V2FPT1KHUh?=
NCI-H345MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfB[3R3UUN3ME20PE41PjhizszNNFvFbWdUSU6JUlXS
TE-5Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDJTWM2OD12OT63NVE5KM7:TR?=MmTMV2FPT1KHUh?=

... Click to View More Cell Line Experimental Data

In vivo VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[3]

Kinase inhibition assays The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl2, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K i = IC50 / (1 + [S]/Kd), where [S] = [ATP] = 2.2 mM, and Kd (of ATP to Abl) = 70 μM. These values are calculated assuming a Kd (ATP) of 70 μM for wild type and H396P Abl kinase domain.

Cell Assay:

[2]

Cell lines CAL-62 cells
Concentrations 5-500 nM
Incubation Time 4 days
Method

The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500  nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500  nM). The cells are pulse labeled with 30  mM BrdU for 2  hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control.

Animal Study:

[1]

Animal Models Female athymic NCr-nu mice bearing HL-60 leukemia cells
Formulation 50% PEG300 in 50 mM phosphate buffer
Dosages 50 mg/kg, 75 mg/kg
Administration Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Harrington EA, et al. Nat Med. 2004, 10(3), 262-267.

[2] Arlot-Bonnemains Y, et al. Endocr Relat Cancer. 2008, 15(2), 559-568.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00500006 Terminated Chronic Myelogenous Leukemia|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Merck Sharp & Dohme Corp. October 2007 Phase 1
NCT00405054 Terminated Leukemia Merck Sharp & Dohme Corp. December 2006 Phase 2
NCT00290550 Terminated Carcinoma, Non-Small-Cell Lung Merck Sharp & Dohme Corp. June 2006 Phase 2
NCT00111683 Completed Chronic Myelogenous Leukemia in Blast Crisis|Lymphocytic Leukemia, B Cell, Acute|Myelodysplastic Syndromes|Myelogenous Leukemia, Chronic Merck Sharp & Dohme Corp. June 2005 Phase 1
NCT02532868 Terminated Cancer Merck Sharp & Dohme Corp. May 2005 Phase 1

view more

Chemical Information

Download VX-680 (Tozasertib, MK-0457) SDF
Molecular Weight (MW) 464.59
Formula

C23H28N8OS

CAS No. 639089-54-6
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 93 mg/mL (200.17 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Aurora Kinase Products

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • CCG-1423

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.

  • ML141

    ML141 is a potent, selective and reversible non-competitive inhibitor of Rho family GTPase cdc42 with IC50 of 200 nM.

  • Alisertib (MLN8237)

    Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

    Features:First orally available inhibitor of Aurora A.

  • Barasertib (AZD1152-HQPA)

    Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

  • Danusertib (PHA-739358)

    Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.

  • ZM 447439

    ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

    Features:An Aurora selective ATP-competitive inhibitor.

  • MLN8054

    MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.

  • MK-5108 (VX-689)

    MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.

  • Aurora A Inhibitor I

    Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.

    Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Recently Viewed Items

Tags: buy VX-680 (Tozasertib, MK-0457) | VX-680 (Tozasertib, MK-0457) supplier | purchase VX-680 (Tozasertib, MK-0457) | VX-680 (Tozasertib, MK-0457) cost | VX-680 (Tozasertib, MK-0457) manufacturer | order VX-680 (Tozasertib, MK-0457) | VX-680 (Tozasertib, MK-0457) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us